Collectively, based on the ESTIMATE algorithms, functional enrichment analysis, PPI network construction, and Cox regression analysis, we suggest CXCL10 is a promising diagnostic and prognostic indicator in PAAD patients which has potential to provide novel immunotherapy insights for PAAD. The gene discussed is CXCL10; the disease is pancreatic adenocarcinoma.